NOVATO, CA (Monday, September 12, 2011) – Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, today announced the release of an empowering new product, Stellaris FISH Probes*. Stellaris FISH (fluorescence in situ hybridization) is a RNA visualization method that allows simultaneous detection, localization, and quantification of individual mRNA molecules at the sub-cellular level in fixed samples. Biosearch currently offers Stellaris FISH probes manufactured on a custom basis, including software for optimum probe design. In addition, premade probe sets for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in human and mouse applications are available.
This novel RNA FISH technology represents a fast and easy-to-use method to achieve conclusive results through compelling images of RNA expression. By enabling scientists to localize and count discrete molecules of mRNA using widefield fluorescence microscopy, Stellaris FISH probes can lead to streamlined studies in stem cell, cancer, pathology, developmental biology, transcription regulation, and neuroscience research.
Stellaris FISH is an effective tool for several key applications. For example, Stellaris probes can be used to reveal up- and down- regulation of gene expression in drug screening studies. Another example is the characterization of tumors by correlating mRNA levels of known oncogenes. Stellaris FISH can also be combined with existing technologies such as qPCR, DNA FISH, IHC (immunohistochemistry), and western blotting to provide complementary information.
Stellaris FISH probes afford increased assay sensitivity over other methods of RNA analysis through a robust mechanism of action. A probe set comprises multiple oligonucleotides with different sequences each with a fluorescent label that collectively bind along the same target transcript to produce a punctate signal. The inherent redundancies of this direct detection method minimizes the possibility of false negatives and false positives. Furthermore, Stellaris FISH probes can bind to partially degraded target mRNAs making them well-suited for formalin-fixed, paraffin-embedded (FFPE) tissue samples.
“Biosearch is very excited to launch Stellaris probes for direct detection in single and multiplexed mRNA FISH applications”, says Marc Beal, Director of Corporate Development at Biosearch Technologies, Inc. “Moreover, we believe that our plans to expand analysis of stochastic gene expression at the single molecule level into high-throughput, automated platforms will enable broader acceptance and market penetration of Stellaris probes and methodologies.”
The Stellaris FISH technology has the potential to revolutionize life science and clinical research because it follows a simple protocol, does not use exotic reagents, is inexpensive and platform-independent, offers same-day results, and is versatile toward many sample types and applications. Scientists may even label Stellaris FISH probes with a number of various dyes, to allow for simultaneous multiplex detection of different RNA targets simultaneously. Biosearch Technologies is pleased to offer this new RNA FISH technology that provides an unparalleled sensitivity and broad applicability. Finally, scientists can address the stochastic nature of gene expression and visualize RNA through direct detection without isolation, purification, and amplification.
*For Research Use Only. Not for use in diagnostic procedures.
This product is sold under license from the University of Medicine and Dentistry of New Jersey and may be used under its patent rights only for Research Use Only.
About Biosearch Technologies, Inc.
Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 certified company, with headquarters in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR and other genomic-based applications.
In addition to basic R&D applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 3003009025), and as such, its GMP and Commercial Services manufacturing processes conform to all applicable GMP requirements per 21 CFR Part 820. Biosearch markets include pharmaceutical, in-vitro diagnostics, biotech, ag/bio, environmental and food testing, public health, and biodefense sectors.
For additional information about Biosearch Technologies, Inc., contact firstname.lastname@example.org or visit www.biosearchtech.com